Mosaic - Polypharmacy- specialist by decree


									                                                                                                      PLAN LOGO

April 9, 2010

Dear Provider:

As part of plan name’s ongoing quality improvement efforts, we periodically identify when members are taking
more than one medication belonging to the same class of drugs for a single health condition. As an example, the
plan name Pharmacy and Therapeutics (P&T) committee has identified patients who are taking two or more
atypical antipsychotic agents.

As the treating physician, you are best qualified to determine which agent and formulation are appropriate on a
case-by-case basis.

However, for the safety of your patients, the P&T committee urges providers to evaluate all treatment programs
that include duplicative therapy in the same therapeutic class. Possible concerns associated with duplicative
therapy are:
          The combined dosage level of medications
          The increased potential for adverse events
          Excessive treatment and patient out-of-pocket costs
          Potentially additive effects of the patient’s over-the-counter medication ingredients

Instances of duplicative therapy can arise when prescribers are switching to an alternative therapy in a class and
the patient, due to a misunderstanding, continues to stay on the therapy(s) intended for discontinuance.

Please review the medications in the antipsychotic class listed in the table below.

                                                              Atypical Antipsychotic Agents
 Preferred                                   List agents

 Nonpreferred                                List agents

Attached are information sheets designed to help your patients learn more about schizophrenia and bipolar
disorder. We have also included important information about the new Medicare Prescription Drug Benefit. Please
take the time to review this information with your patients and/or their caregivers, as appropriate.

We appreciate your continued support in our efforts to encourage quality care. If you have any questions, please
contact contact name, plan name / department name, at phone number and/or Web site address.


MEDICAL DIRECTOR NAME                                         PHARMACY DIRECTOR NAME

Medical Director                                              Pharmacy Director


To top